Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14087517 | 0.91 | GPR119 (0.67) | GPR119ALKHRH3CHEK2ALDH1A1 | |
| SCHEMBL3283465 | 0.88 | GPR119 (0.64) | GPR119ALKHRH3CHEK2AR | |
| SCHEMBL951749 | 0.87 | GPR119 (0.50) | GPR119ALKCHEK2ALDH1A1PDE4B | |
| SCHEMBL8089440 | 0.86 | GPR119 (0.61) | GPR119ALKHRH3AR | |
| SCHEMBL15888739 | 0.86 | GPR119 (0.61) | GPR119ALKHRH3CHEK2ALDH1A1 | |
| SCHEMBL25392938 | 0.86 | GPR119 (0.64) | GPR119ALKHRH3CHEK2ALDH1A1 | |
| SCHEMBL3670130 | 0.85 | AR (0.48) | GPR119HRH3AR | |
| SCHEMBL16752620 | 0.85 | AR (0.47) | GPR119ALKHRH3AR | |
| SCHEMBL30272627 | 0.84 | GPR119 (0.61) | GPR119ALKHRH3CHEK2 | |
| SCHEMBL22462765 | 0.84 | GPR119 (0.61) | GPR119ALKHRH3CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240441-B1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI SA (FR) | 2015-06-03 | — | — | EP | claimed |
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | claimed |
| EP-2240441-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | claimed |
| WO-2009080335-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | claimed |
| EP-2729463-B1 | SUBSTITUTED PHENYL COMPOUNDS | SANOFI SA (FR) | 2015-07-29 | — | — | EP | disclosed |
| EP-2729463-B1 | SUBSTITUTED PHENYL COMPOUNDS | SANOFI SA (FR) | 2015-07-29 | — | — | EP | disclosed |
| EP-2240441-B1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI SA (FR) | 2015-06-03 | — | — | EP | disclosed |
| US-8785642-B2 | Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound | SANOFI (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785642-B2 | Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound | SANOFI (FR) | 2014-07-22 | — | — | US | disclosed |
| EP-2729463-A1 | SUBSTITUTED PHENYL COMPOUNDS | SANOFI (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8716481-B2 | Process for the preparation of 6-substituted-1-(2H)-isoquinolinones | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| WO-2013007502-A1 | SUBSTITUTED PHENYL COMPOUNDS | SANOFI (FR) | 2013-01-17 | — | — | WO | disclosed |
| US-20130012711-A1 | SUBSTITUTED PHENYL COMPOUNDS | SANOFI (FR) | 2013-01-10 | — | — | US | disclosed |
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2240441-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009080335-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | CYP1B1, CYP1A1, NQO1 | GPR119 3335/4885ALK 1710/4885HRH3 1906/4885 |
| US-20130012711-A1 | SUBSTITUTED PHENYL COMPOUNDS | PAH, NQO1, CYP1B1 | GPR119 3631/4885ALK 668/4885HRH3 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.